核糖体功能障碍是SLFN14相关血小板减少症的基础
研究在永生化巨核细胞系及患者血小板中建模SLFN14 K219N变异,发现SLFN14缺陷导致前血小板形成和线粒体组织障碍、rRNA降解,血小板转录组中134个核糖体蛋白基因上调,mTORC1抑制加重rRNA降解,提示mTORC1协调的核糖体生物合成失调是该病机制。
要点
- SLFN14 K219N巨核细胞主要表现为前血小板形成和线粒体组织缺陷。
- SLFN14缺陷的血小板和成熟巨核细胞出现rRNA降解迹象。
- mTORC1抑制(雷帕霉素)进一步加重SLFN14 K219N巨核细胞的rRNA降解。
核心结论
- SLFN14相关血小板减少症的疾病机制为mTORC1协调的核糖体生物合成失调。
研究设计与样本
- 研究在永生化巨核细胞系(imMKCL)中建模SLFN14 K219N变异,并表征携带该变异患者的血小板转录组。
- 对2例患者和19例健康对照的血小板总RNA进行测序。
主要发现
- 杂合及纯合SLFN14 K219N imMKCL来源的巨核细胞及患者血液干细胞来源的巨核细胞主要表现为前血小板形成和线粒体组织缺陷。
- SLFN14缺陷的血小板和成熟巨核细胞显示rRNA降解迹象,而未分化imMKCL细胞和粒细胞中无此现象。
- 差异基因表达分析得到2999个显著上调和2888个显著下调基因(|log2 fold change| >1,false discovery rate <0.05)。
- 下调基因未富集于任何生物学通路,上调基因富集于(线粒体)翻译和转录相关通路,其中134个核糖体蛋白基因显著上调。
- SLFN14 K219N巨核细胞中通过增加mTORC1信号导致的线粒体核糖体蛋白基因上调似乎是对rRNA降解的代偿反应。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pathogenic missense variants in SLFN14, which encode an RNA endoribonuclease protein that regulates ribosomal RNA (rRNA) degradation, are known to cause inherited thrombocytopenia (TP) with impaired platelet aggregation and adenosine triphosphate secretion. Despite mild laboratory defects, the patients displayed an obvious bleeding phenotype. However, the function of SLFN14 in megakaryocyte (MK) and platelet biology remains unknown. This study aimed to model the disease in an immortalized MK cell line (imMKCL) and to characterize the platelet transcriptome in patients with the SLFN14 K219N variant. MK derived from heterozygous and homozygous SLFN14 K219N imMKCL and stem cells of blood from patients mainly presented with a defect in proplatelet formation and mitochondrial organization. SLFN14-defective platelets and mature MK showed signs of rRNA degradation; however, this was absent in undifferentiated imMKCL cells and granulocytes. Total platelet RNA was sequenced in 2 patients and 19 healthy controls. Differential gene expression analysis yielded 2999 and 2888 significantly (|log2 fold change| >1, false discovery rate <0.05) up- and downregulated genes, respectively. Remarkably, these downregulated genes were not enriched in any biological pathway, whereas upregulated genes were enriched in pathways involved in (mitochondrial) translation and transcription, with a significant upregulation of 134 ribosomal protein genes (RPGs). The upregulation of mitochondrial RPGs through increased mammalian target of rapamycin complex 1 (mTORC1) signaling in SLFN14 K219N MK seems to be a compensatory response to rRNA degradation. mTORC1 inhibition with rapamycin resulted in further enhanced rRNA degradation in SLFN14 K219N MK. Taken together, our study indicates dysregulation of mTORC1 coordinated ribosomal biogenesis is the disease mechanism for SLFN14-related TP.
引用
- Ver Donck F, Ramaekers K, Thys C, et al. Ribosome dysfunction underlies SLFN14-related thrombocytopenia. Blood. 2023. PMID: 36790527. doi:10.1182/blood.2022017712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。